Follow The Filings

ALMR Alamar Biosciences

Alamar Biosciences earnings company data as of 4:47 AM ET 10/12

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by ALMR's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ALMR insider trades
  • $8M bought by 2 insiders
  • $10.8M sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Qiming Corporate GP VI, Ltd. 10% owner, +6 joint filers
    Sale
    $5.9M 217,512 shares at $27.35 11% of stake
    Traded Oct 19–20 Filed Oct 21
    ↗
  2. Qiming Corporate GP VI, Ltd. 10% owner, +6 joint filers
    Sale
    $4.8M 173,673 shares at $27.73 8.4% of stake
    Traded Oct 15–16 Filed Oct 19
    ↗
  3. Nicholas Naclerio Director
    Buy
    $4M 235,294 shares at $17.00 +87% to stake
    Traded Apr 20 Filed Apr 20
    ↗

Also filed in the last 12 months, not counted as buying or selling: 20 other transactions, 17 conversions, and 7 stock grants.

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
8-K 5.02 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13D — Filing Doc
SCHEDULE 13D — Filing Doc
8-K 5.03,8.01,9.01 Filing Doc
424B4 Filing Doc
S-1/A Filing Doc
S-1/A Filing Doc
S-1 Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.